381 related articles for article (PubMed ID: 20148455)
1. Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary.
Karaferic A; Jovanovic D; Jelic S
J BUON; 2009; 14(4):635-9. PubMed ID: 20148455
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
[TBL] [Abstract][Full Text] [Related]
3. Expression of estrogen receptors alpha and beta, and progesterone receptors A and B in human mucinous carcinoma of the endometrium.
Shabani N; Mylonas I; Jeschke U; Thaqi A; Kuhn C; Puchner T; Friese K
Anticancer Res; 2007; 27(4A):2027-33. PubMed ID: 17649817
[TBL] [Abstract][Full Text] [Related]
4. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis.
Wong KK; Lu KH; Malpica A; Bodurka DC; Shvartsman HS; Schmandt RE; Thornton AD; Deavers MT; Silva EG; Gershenson DM
Int J Gynecol Pathol; 2007 Oct; 26(4):404-9. PubMed ID: 17885490
[TBL] [Abstract][Full Text] [Related]
5. Analysis of potential prognostic factors in 111 patients with ovarian cancer.
Hornung R; Urs E; Serenella E; Edward W; Ursula S; Urs H; Daniel F
Cancer Lett; 2004 Mar; 206(1):97-106. PubMed ID: 15019165
[TBL] [Abstract][Full Text] [Related]
6. Expression of the estrogen and progesterone receptors as prognostic factor in serous ovarian cancers.
Buchynska LG; Iurchenko NP; Grinkevych VM; Nesina IP; Chekhun SV; Svintsitsky VS
Exp Oncol; 2009 Mar; 31(1):48-51. PubMed ID: 19300417
[TBL] [Abstract][Full Text] [Related]
7. Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma.
Liu JF; Hirsch MS; Lee H; Matulonis UA
Gynecol Oncol; 2009 Dec; 115(3):401-6. PubMed ID: 19796795
[TBL] [Abstract][Full Text] [Related]
8. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
9. Clinical factors and biomarkers in ovarian tumors development.
Vrabie CD; Petrescu A; Waller M; Dina I
Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
[TBL] [Abstract][Full Text] [Related]
10. Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIc serous cystadenocarcinoma of the ovary.
Geisler JP; Wiemann MC; Miller GA; Geisler HE
Gynecol Oncol; 1996 Mar; 60(3):424-7. PubMed ID: 8774651
[TBL] [Abstract][Full Text] [Related]
11. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
12. Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer.
Borgoño CA; Kishi T; Scorilas A; Harbeck N; Dorn J; Schmalfeldt B; Schmitt M; Diamandis EP
Clin Cancer Res; 2006 Mar; 12(5):1487-93. PubMed ID: 16533772
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen value as a marker in breast cancer.
Narita D; Cimpean AM; Anghel A; Raica M
Neoplasma; 2006; 53(2):161-7. PubMed ID: 16575473
[TBL] [Abstract][Full Text] [Related]
14. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
Sieh W; Köbel M; Longacre TA; Bowtell DD; deFazio A; Goodman MT; Høgdall E; Deen S; Wentzensen N; Moysich KB; Brenton JD; Clarke BA; Menon U; Gilks CB; Kim A; Madore J; Fereday S; George J; Galletta L; Lurie G; Wilkens LR; Carney ME; Thompson PJ; Matsuno RK; Kjær SK; Jensen A; Høgdall C; Kalli KR; Fridley BL; Keeney GL; Vierkant RA; Cunningham JM; Brinton LA; Yang HP; Sherman ME; García-Closas M; Lissowska J; Odunsi K; Morrison C; Lele S; Bshara W; Sucheston L; Jimenez-Linan M; Driver K; Alsop J; Mack M; McGuire V; Rothstein JH; Rosen BP; Bernardini MQ; Mackay H; Oza A; Wozniak EL; Benjamin E; Gentry-Maharaj A; Gayther SA; Tinker AV; Prentice LM; Chow C; Anglesio MS; Johnatty SE; Chenevix-Trench G; Whittemore AS; Pharoah PD; Goode EL; Huntsman DG; Ramus SJ
Lancet Oncol; 2013 Aug; 14(9):853-62. PubMed ID: 23845225
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma.
Tanabe H; Nishii H; Sakata A; Suzuki K; Mori Y; Shinozaki H; Watanabe A; Ochiai K; Yasuda M; Tanaka T
Gynecol Oncol; 2004 Sep; 94(3):735-9. PubMed ID: 15350366
[TBL] [Abstract][Full Text] [Related]
16. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
17. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
18. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
Sharif MA; Mamoon N; Mushtaq S; Khadim MT
J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
[TBL] [Abstract][Full Text] [Related]
19. B7-H4 overexpression in ovarian tumors.
Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
[TBL] [Abstract][Full Text] [Related]
20. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
Ayhan A; Guven S; Guven ES; Kucukali T
Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]